Just a couple of years ago, generics were all the rage in pharmaceutical development programs. Big pharma companies scrambled for ways to create generics franchises that would enable them to offer a broad array of products to managed care customers. But now, with HMR's sale of its Rugby-Darby Group to Watson Pharmaceuticals, we seem to be in the midst of a major bail out. It's now clear that the smartest generics strategy is a no-generics strategy.
You may also be interested in...
Latest warnings also include second and third businesses in US cannabidiol and hemp sector found making unlawful claims for treating and preventing COVID-19. Four of five firms warned apparently responded by removing violative claims from websites and social media posts.
In addition to our daily in-depth coverage of key regulatory events relating to the coronavirus pandemic, we’re bringing you selected brief insights into the impact on biopharma commercial activities.
TytoCare has raised $50m in funding, which will be used to expand the reach of its telehealth solutions.